The phase 3, open-label, single arm BOND-003 trial also evaluated cretostimogene in cohort P with papillary-only high-grade NMIBC who failed prior BCG therapy.
Kolschowsky Research and Education Institute at Sarasota Memorial Hospital is seeking candidates diagnosed with ...
Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...
Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment ...
The recommendation addresses a long-standing treatment gap for patients facing bladder removal after standard therapy fails.
The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...
Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its ...
ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has ...
EMA recommends conditional authorization for ImmunityBio's Anktiva with BCG after a 71% complete response rate in ...
Theralase Technologies ( ($TSE:TLT) ) has provided an announcement. Theralase Technologies has closed a non-brokered private placement of ...
RARITAN, N.J., July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback